Exhibition network integration link resources Chinese pharmaceutical enterprises to expand global business opportunities welcome bureau

The risk of bad debts has increased sharply, exchange rate fluctuations have intensified, and international logistics costs have increased... At present, the epidemic is constantly amplifying external risks of foreign trade in medicine, prompting countries to pay more attention to public health security, and accelerating the restructuring process of the global pharmaceutical industry and supply chain.

The reshaping of the global pharmaceutical industry not only brings challenges to the international development of Western medicine and other Chinese pharmaceutical industries, but also contains new opportunities for industrial optimization and upgrading. On the one hand, the protection of pharmaceutical supply chain in various countries provides more favorable conditions for Chinese pharmaceutical companies to "go global". The demand for epidemic prevention and resistance will also increase the global dependence on China's pharmaceutical supply chain in the short term. On the other hand, countries encourage regional development of pharmaceutical supply chain will significantly intensify international competition in the industry.

"Foreign trade enterprises of western medicine should carefully develop customers, carefully check contracts, and actively prevent and avoid external risks by means of foreign exchange lock and credit insurance." China Chamber of Commerce for The Import and Export of Medicines and Health Products, Vice director of the Western medicine department Rongxian said in Beijing on Sept. 10, current, industry enterprises to avoid vicious competition and short-term speculation, can reasonably raise prices, and make full use of authoritative channels and online platforms to develop the market.

Encouragingly, Chinese pharmaceutical companies have actively responded to the difficulties and made positive contributions to stabilizing the supply of global pharmaceutical industry. Data from the Medical Insurance Chamber of Commerce shows that in the first half of the year, China's import and export of western medicine reached 45.693 billion US dollars, up 9.4% year on year. Exports totaled US $23.640 billion, up 13.13%. Imports totaled US $22.053 billion, up 5.65 percent.

In the changing situation for development, Rongxian reminds pharmaceutical enterprises to tamp the internal strength, play a solid foundation, accelerate the transformation and upgrading. At the product level, strengthen the differentiation advantage, play a good combination of products; From the perspective of industrial chain, accelerate vertical integration of upstream and downstream industrial chain, establish closer relations with suppliers, and promote the upgrading of its own industrial chain; In terms of market development, we will intensify the development of the "One Belt And One Road" market, further improve the construction of overseas channels, and at the same time tap into the potential of the domestic market and make full use of both domestic and foreign markets and resources.

According to Rong, innovation and cost control are particularly important for pharmaceutical companies as they promote transformation and upgrading. The international development of pharmaceutical enterprises should explore the development of more forms of international cooperation in addition to the mere "going out" of products.

On the same day of the world Pharmaceutical Raw Materials China Exhibition and The World Pharmaceutical Machinery, Packaging Equipment and Materials China exhibition (CPhI & P-MEC China) overseas promotion through train and online live broadcast of pharmaceutical foreign trade situation, the organizer announced that the exhibition will be held in Shanghai New International Expo Center from December 16 to 18. In this special period, the exhibition will join hands with participating pharmaceutical enterprises to demonstrate to the world that China's pharmaceutical industry chain is capable and determined to maintain the safety and smooth operation of the global pharmaceutical supply chain, and to demonstrate China's strength and responsibility.

Comply with the online exhibition industry development trend of "exhibition network convergence", CPhI & P - MEC China will cooperate with offline exhibition launched in December 2020 version 2.0 Virtual Expo Connect online exhibition (VEC), to collect all resources, the whole channel "combination", for the majority of exhibitors from quantity, quality, and the optimization of the audience at home and abroad, to create effective links and business opportunities overseas.

On the basis of the first VEC in June, the exhibition will upgrade a number of services and functions, such as online exhibition hall, cloud business negotiation, live broadcast on cloud, virtual shopping exhibition, etc., to create a two-way trade exchange platform integrating display, docking, negotiation and interaction. At the same time, the exhibition site in December will set up VEC super large digital center, equipped with private online reception room, entrepreneurs live interview room, overseas specially invited buyers video negotiation room, to help exhibitors to connect overseas customers without obstacles.